InsiderSignal.AI

InsiderSignal.ai

PTCT - Ptc Therapeutics, Inc.

Insider Sale by Gravier Pierre (CFO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

3 days ago, Gravier Pierre, serving as CFO at Ptc Therapeutics, Inc. (PTCT), sold 2,992 shares at $69.36 per share, for a total transaction value of $207,525.00. Following this transaction, Gravier Pierre now holds 87,318 shares of PTCT.

This sale represents a 3.00% decrease in Gravier Pierre's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Wednesday, February 18, 2026 and publicly disclosed via SEC Form 4 filing on Friday, February 20, 2026, 2 days after the trade was made.

Ptc Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Gravier Pierre

CFO

Pierre Gravier is the Chief Financial Officer (CFO) of PTC Therapeutics, Inc. (PTCT), a biopharmaceutical company focused on rare diseases, a position he has held since July 2023.[[1]](https://www.pharmaceuticalcommerce.com/view/ptc-therapeutics-appoints-pierre-gravier-as-cfo)[[2]](https://fintool.com/app/research/companies/PTCT/people/pierre-gravier)[[3]](https://www.ptcbio.com/team/leadership/pierre-gravier/) Aged 41, Gravier recently reported trading activity, including the disposal of common shares in early 2026.[[7]](https://www.webull.com.my/news-detail/14169128497071104) Gravier brings over 17 years of experience as an investment banker, venture capitalist, and scientist.[[1]](https://www.pharmaceuticalcommerce.com/view/ptc-therapeutics-appoints-pierre-gravier-as-cfo)[[3]](https://www.ptcbio.com/team/leadership/pierre-gravier/) His career highlights include serving as Managing Director in the healthcare group at Perella Weinberg Partners from 2013 to July 2023, advising biopharma firms on M&A, joint ventures, licensing, and capital raises; healthcare investment banking at Barclays Capital in London; venture capital analysis at Société Générale Asset Management in Paris; and starting as a scientist at Ferring Pharmaceuticals.[[1]](https://www.pharmaceuticalcommerce.com/view/ptc-therapeutics-appoints-pierre-gravier-as-cfo)[[2]](https://fintool.com/app/research/companies/PTCT/people/pierre-gravier)[[3]](https://www.ptcbio.com/team/leadership/pierre-gravier/) He holds a Master’s in Finance from ESCP Business School and an M.S. in Bioengineering from the University of Technology of Compiègne, and serves on the board of Cassava Sciences, Inc. since December 2023.[[2]](https://fintool.com/app/research/companies/PTCT/people/pierre-gravier)[[3]](https://www.ptcbio.com/team/leadership/pierre-gravier/)

View full insider profile →

Trade Price

$69.36

Quantity

2,992

Total Value

$207,525.00

Shares Owned

87,318

Trade Date

Wednesday, February 18, 2026

3 days ago

SEC Filing Date

Friday, February 20, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Ptc Therapeutics, Inc.

Company Overview

No company information available
View news mentioning PTCT

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4154558

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime